A Randomised Comparison of Oestrogen Suppression with Anastrozole and Formestane in Postmenopausal Patients with Advanced Breast Cancer

Oncology (Switzerland)

Volumn 54, Issue 2, 1997, Pages 19-22

  Kleeberg, U R ^a   Dowsett, M ^a   Carrion, R P ^a   Dodwell, D J ^a   Vorobiof, D A ^a   Aparicio, L A ^a   Robertson, J F R ^a  

^a Practice for Medical Oncology   (Germany)

Author keywords

Anastrozole; Aromatase inhibitors; Comparative trials; Formestane; Oestradiol suppression

Indexed keywords

ANASTROZOLE; ESTRADIOL; ESTROGEN; FORMESTANE;

ADULT; AGED; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; TREATMENT OUTCOME; TRIAZOLES;

EID: 0030669680     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227752     Document Type: Article

References (7)

1. Lipton A, Harvey HA, Santen RJ: Randomised trial of aminogiutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 1982;42: 3434-3436.
2. Coombes RC. Powles TJ. Easton D: Adjuvant aminogiutethimide therapy for postmenopausal patients with primary breast cancer. Cancer Res 1987;47:2496-2499.
3. Santen RJ, Manni A, Harvey H, Redmond C: Endocrine treatment of breast cancer in women. Endocr Rev 1990; 11;221.
4. Geisler J, King N, Dowsctt M, Ottestad L, Lundgrcn S, Walton P, Kormeset PO, Lonning PE: Influence of anastrozolc (Arimidex). a selective. non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286-1291.
5. Jones S, MacNcill FA, Jacobs S, fanning PE, Dowsctt M, Powles TJ: The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 1992;28A: 1712-1716.
6. Dowsett M, Cunningham DC, Stein RC, Evans S, Dehennin L, Hedley A, Coombes RC: Dose-related endocrine effects of pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989:49:1306-1312.
7. Miller WR: Aromatase inhibitors. Endocr Rc-lat Cancer 1996:3:65-79.